- About Us
- Career Center
- Nano-Social Network
- Nano Consulting
- My Account
* "Emerging Company of the Year in Asia Pacific" in biomedical sciences
* "Curiox is a potential industry leader within 10 years"
* Expanding in USA, Europe and Japan
Curiox was awarded "Emerging Company of the Year 2010 in Asia Pacific", on 12th March, by BioSpectrum Asia. BioSpectrum Asia is a leading B2B media platform covering the life sciences industry in the Asia Pacific region.
Curiox and other Asia Pacific companies were assessed on the basis of their achievements and potential for future growth to determine companies that shall emerge as industry leaders, in the biomedical science and biotechnology sectors, in the coming decade. BioSpectrum's team of industry experts evaluated all aspects of the organizations' performance and public profile, prior to nominating Curiox as the winner of the award in the sector biomedical sciences. The award was given to five more companies from other sectors in life sciences and medical technologies.
Curiox's "Emerging Company of the Year" award comes hot on the heels of Curiox's LabAutomation2010 "Innovation AveNEW" award, earlier this year; as one of the industry's most innovative laboratory automation technology. This magnitude of worldwide industry acceptance and excitement for is welcomed by the young Singaporean start-up Curiox; and comes at a crucial time as Curiox begins to expand its products to overseas markets.
"It is truly an honour to be selected with top companies in Asia who have been around much longer than Curiox. These awards demonstrate to our customers, partners and competitors that our DropArray™ technology is truly innovative, and is recognized by industry experts (on a global scale) to be beneficial and potentially disruptive to the laboratory automation industry," comments Curiox's CEO Dr Namyong Kim.
Curiox's patent-pending DropArray™ technology provides a next-generation "wall-less" microtiter platform, and complimentary washing instrument, to provide researchers with better quality of data, 10 - 50 times savings in sample and reagent consumption, and up to 60 % assay time reduction. Additionally, DropArray™ technology promotes integration with liquid handling systems by maintainaining reproducibility and compatibility with existing microtiter plate detection systems.
Curiox Biosystems intends to penetrate the United States, European and Japanese laboratory markets this year through strategic partnerships and distributors.
According to BioSpectrum Asia, it has a readership of over 150,000 (including print magazine, online-edition and website) of which a large majority represent key decision makers in the Pharma and Biotech industry.
The Nanostart Singapore Early Stage Venture Fund I holds almost 19% in Curiox Biosystems.
This notice constitutes neither an offer to sell nor a solicitation of offers to purchase or subscribe to securities. There will be no public offering of securities of Nanostart AG in conjunction with the existing listing of its shares in the "Entry Standard" segment of the regulated unofficial market (Freiverkehr) on the Frankfurt Stock Exchange. This notice does not constitute a securities prospectus. Neither this notice nor the information contained within is intended for direct or indirect distribution within the United States of America, Canada, Australia or Japan.
About Nanostart AG
Nanostart AG is the world’s leading nanotechnology investment company. The Frankfurt-based company provides venture capital financing for nanotechnology companies in various growth phases. It also provides the benefits of its experience and expertise to developers of financial instruments and to investors in the nanotechnology sector. For further information about the company, please visit www.nanostart.de.
About Curiox Biosystems Pte Ltd
Curiox Biosystems has a vision to accelerate the progress of life sciences and drug discovery through better miniaturization. Curiox is a bioinstrumentation company enabling the miniaturization of heterogeneous bioassay for researchers working in life sciences, drug discovery, and diagnostics. Curiox’s patented miniaturization platform, DropArray™, provides up to 1,000 times savings in sample and reagent consumption, and up to 10 times reduction in assay time. The company is located in Singapore, the biomedical hub of Southeast Asia. The company is a spin-off from Institute of Bioengineering and Nanotechnology (IBN) backed primarily by Nanostart and Exploit Technologies, the commercializing arm of Singapore’s Agency for Science, Technology and Research (A*STAR). For further information, please visit www.curiox.com.
For more information, please click here
Dr. Hans Joachim Dürr
phone: +49 (0)69-21 93 96 111
fax: +49 (0)69-21 93 96 122
Copyright © Nanostart AGIf you have a comment, please Contact us.
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
|Related News Press|
News and information
Two UCSB Professors Receive Early Career Research Awards: The Department of Energy’s award for young scientists acknowledges UC Santa Barbara’s standing as a top tier research institution May 29th, 2015
Arrowhead to Present at Jefferies 2015 Healthcare Conference May 27th, 2015
Physicists solve quantum tunneling mystery: ANU media release: An international team of scientists studying ultrafast physics have solved a mystery of quantum mechanics, and found that quantum tunneling is an instantaneous process May 27th, 2015
This Slinky lookalike 'hyperlens' helps us see tiny objects: The photonics advancement could improve early cancer detection, nanoelectronics manufacturing and scientists' ability to observe single molecules May 23rd, 2015
New technique speeds nanoMRI imaging: Multiplexing technique for nanoscale magnetic resonance imaging developed by researchers in Switzerland cuts normal scan time from two weeks to two days May 28th, 2015
Nanotechnology identifies brain tumor types through MRI 'virtual biopsy' in animal studies: If results are confirmed in humans, tumor cells could someday be diagnosed by MRI imaging and treated with tumor-specific IV injections; new NIH grant will fund future study May 27th, 2015